Company: TELO
Filing Date: 2025-11-10
Form Type: 10-Q
Source: 0001493152-25-021496
Chunk: 0

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-11-10
Form: 10-Q
Item: Item 1
Chunk 0
---
CONDENSED
BALANCE SHEETS

    September
    30,  
    December
    31, 

    2025  
    2024 

    (unaudited)  

    ASSETS 

    Current assets: 

    Cash 
    $7,329,298  
    $1,266,131 
  
    Prepaid expenses 
     72,819  
     57,874 
  
    Total current assets 
     7,402,117  
     1,324,005 

    Total assets 
    $7,402,117  
    $1,324,005 

    LIABILITIES AND STOCKHOLDERS’ EQUITY 

    Current liabilities: 

    Trade accounts payable and accrued liabilities 
    $329,375  
    $587,536 
  
    Due to related parties 
     93,432  
     93,432 
  
    Total current liabilities 
     422,807  
     680,968 

    Total liabilities 
    $422,807  
    $680,968 

    Stockholders’ Equity 

    Preferred Stock, no par value, 100,000,000 shares authorized and none issued or outstanding. 
     -  
     - 
  
    Common Stock, no par value; 300,000,000 shares authorized, 33,830,971 and 29,762,671 shares issued and outstanding at September 30, 2025 and December 31, 2024, respectively. 
     -  
     - 
  
    Additional paid-in capital 
     45,928,180  
     31,239,895 
  
    Accumulated deficit 
     (38,948,870) 
     (30,596,858)
  
    Total stockholders’ equity 
     6,979,310  
     643,037 
  
    Total liabilities and stockholders’
    equity 
    $7,402,117  
    $1,324,005 

See
notes to condensed unaudited financial statements

3

TELOMIR
PHARMACEUTICALS, INC.

CONDENSED
STATEMENTS OF OPERATIONS

FOR
THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2025 AND 2024

(Unaud